Hepatic clearance of drugs. I. Theoretical considerations of a "well-stirred" model and a "parallel tube" model. Influence of hepatic blood flow, plasma and blood cell binding, and the hepatocellular enzymatic activity on hepatic drug clearance.
about
Clinical pharmacology of midazolam in neonates and children: effect of disease-a reviewSpatio-temporal simulation of first pass drug perfusion in the liverSimulating microdosimetry in a virtual hepatic lobuleRepresentative Sinusoids for Hepatic Four-Scale Pharmacokinetics SimulationsApplication of a physiologically based pharmacokinetic model to assess propofol hepatic and renal glucuronidation in isolation: utility of in vitro and in vivo data.Prediction of oral clearance from in vitro metabolic data using recombinant CYPs: comparison among well-stirred, parallel-tube, distributed and dispersion models.A comparative evaluation of models to predict human intestinal metabolism from nonclinical data.Prediction of hepatic clearance in human from in vitro data for successful drug development.Determination of the most influential sources of variability in tacrolimus trough blood concentrations in adult liver transplant recipients: a bottom-up approachVariability in biological monitoring of solvent exposure. I. Development of a population physiological model.Dynamic determination of kinetic parameters for the interaction between polypeptide hormones and cell-surface receptors in the perfused rat liver by the multiple-indicator dilution methodKinetic aspects of drug disposition in the lungs.An integrated drug-likeness study for bicyclic privileged structures: from physicochemical properties to in vitro ADME properties.Incorporating target-mediated drug disposition in a minimal physiologically-based pharmacokinetic model for monoclonal antibodies.Impact of ignoring extraction ratio when predicting drug-drug interactions, fraction metabolized, and intestinal first-pass contribution.Implications and consequences of enzyme induction on preclinical and clinical drug development.Drug structure-transport relationshipsPharmacokinetics of enzalutamide, an anti-prostate cancer drug, in rats.The effects of chronic renal insufficiency on the pharmacokinetics of doxycycline in man.Stable oral availability of sustained release propranolol when co-administered with hydralazine or food: evidence implicating substrate delivery rate as a determinant of presystemic drug interactions.Pharmacokinetics and molecular detoxicationThe effect of therapeutic hypothermia on drug metabolism and response: cellular mechanisms to organ functionPharmacokinetic modeling of absorption behavior of 9-aminocamptothecin (9-AC) released from colon-specific HPMA copolymer-9-AC conjugate in rats.Influence of mild and moderate hepatic impairment on axitinib pharmacokineticsCardiac arrest and therapeutic hypothermia decrease isoform-specific cytochrome P450 drug metabolism.Prediction of a potentially effective dose in humans for BAY 60-5521, a potent inhibitor of cholesteryl ester transfer protein (CETP) by allometric species scaling and combined pharmacodynamic and physiologically-based pharmacokinetic modellingMetabolite profiling and pharmacokinetic evaluation of hydrocortisone in a perfused three-dimensional human liver bioreactorIn vitro-in vivo correlations for drugs eliminated by glucuronidation: investigations with the model substrate zidovudine.Mild hypothermia decreases fentanyl and midazolam steady-state clearance in a rat model of cardiac arrest.Across-Species Scaling of Monoclonal Antibody Pharmacokinetics Using a Minimal PBPK Model.A multi-scale modeling framework for individualized, spatiotemporal prediction of drug effects and toxicological risk.Artemether/lumefantrine in the treatment of uncomplicated falciparum malaria.Bosentan, a new endothelin receptor antagonist: prediction of the systemic plasma clearance in man from combined in vivo and in vitro data.Advanced pharmacokinetic models based on organ clearance, circulatory, and fractal concepts.Intestinal permeability and its relevance for absorption and elimination.Physiologically based approaches towards the prediction of pharmacokinetics: in vitro-in vivo extrapolation.Modeling kinetics of subcellular disposition of chemicals.Protein binding predictions in infantsDevelopment of a paediatric population-based model of the pharmacokinetics of rivaroxaban.Intracellular drug concentrations and transporters: measurement, modeling, and implications for the liver.
P2860
Q27006333-64105BD4-FA36-4A11-94F6-B35EADCA9A36Q27322901-35D15B0D-FC3C-4AE0-A5CB-22C72E44CEDFQ28473754-F871441B-D5E5-49A2-824C-A60BB47FCDA3Q28546872-CF82DF23-B0E1-462C-8960-BC2293F22926Q30585329-1864DE28-73F7-481A-8099-0EF79326B764Q31007816-E3075E3B-0A20-4D33-95C8-9F9CDA119A4CQ31159063-A20C5014-A535-4E4B-83A7-C78345B9846BQ33437736-FD622A4F-1D2F-4158-BA9E-1C4438497B5EQ33574176-8069963C-3E83-479E-944B-C58234B1B815Q33577718-2D8C4167-7B60-41C5-8384-701E90E91354Q33667149-719689FE-D97D-434E-B61D-D2D0DDA4B38EQ33673686-CC888371-104B-4768-80E9-DF4676C1EACCQ33888168-8D490F7C-8D81-456D-AC92-05ED2083D90EQ34204024-62CE206E-2D21-4599-B4E3-F1B21BD0D232Q34257513-63ED12CC-2019-4974-8034-4E59BBB323B5Q34378928-93448952-239C-4A98-86A4-04BE601303A2Q34420259-BBCE605F-86CA-4056-AED0-6E922BEDECF4Q34475712-C5B7ACE0-850F-40E7-8ED2-EB0AAD47255AQ34513103-EE64FE58-FF80-44A8-8E8F-D5DC5A69A530Q34620717-77106AA3-0F7F-4C58-8A9E-27611B7120BFQ34636589-A0A96CB3-581D-4A71-BECD-440E0B67BC59Q35048082-D2FC243C-5982-45AD-9E5A-3537CA180A1FQ35104714-30FCC76C-D880-4DAF-A8AF-F7616E637192Q35209594-DD257613-20D8-423E-8ED2-7ECD3D6F7263Q35579550-BA5D7FC5-0960-4081-B435-0D438C41CFE0Q35718576-3FF5660D-2841-4BF3-A0C7-7514D658B60BQ35745230-E52B5683-C2FE-4B38-B536-621A007A47E3Q35804150-7BF06D80-B15A-4BFE-AFF1-85823EFA96BFQ35840167-B6837088-99C5-4F54-BFD5-974FECD341DDQ36087076-8F94D77D-62C4-4D6B-AC40-973B920F72C9Q36550939-3CF174C8-279B-46AD-B5D8-6D54340B0561Q36681333-52BDD77C-F4DC-4AA1-93AE-C8513BB4390BQ36808975-FA603363-D862-4A9A-96DE-891D47246786Q36956680-D4286FAB-0821-4BBE-BD23-D6C146553422Q36985043-1872D259-44D7-4ACE-B1DC-77E6C28B11A5Q37008900-4E242A6A-1D9C-4215-8A68-267511D1AEF0Q37194304-687EE462-E0EF-4BB7-B3CA-1C8C141456A3Q37361786-6AF116FC-A2A9-4D30-AE6C-1ED511CFE797Q37470692-8E8A92D0-59B4-47E0-B763-B95EC64288A2Q37504548-40FE62EC-5E48-4C5B-B947-17AE6CC48B4A
P2860
Hepatic clearance of drugs. I. Theoretical considerations of a "well-stirred" model and a "parallel tube" model. Influence of hepatic blood flow, plasma and blood cell binding, and the hepatocellular enzymatic activity on hepatic drug clearance.
description
1977 nî lūn-bûn
@nan
1977年の論文
@ja
1977年学术文章
@wuu
1977年学术文章
@zh
1977年学术文章
@zh-cn
1977年学术文章
@zh-hans
1977年学术文章
@zh-my
1977年学术文章
@zh-sg
1977年學術文章
@yue
1977年學術文章
@zh-hant
name
Hepatic clearance of drugs. I. ...... ity on hepatic drug clearance.
@en
Hepatic clearance of drugs. I. ...... ity on hepatic drug clearance.
@nl
type
label
Hepatic clearance of drugs. I. ...... ity on hepatic drug clearance.
@en
Hepatic clearance of drugs. I. ...... ity on hepatic drug clearance.
@nl
prefLabel
Hepatic clearance of drugs. I. ...... ity on hepatic drug clearance.
@en
Hepatic clearance of drugs. I. ...... ity on hepatic drug clearance.
@nl
P2860
P356
P1476
Hepatic clearance of drugs. I. ...... ity on hepatic drug clearance.
@en
P2093
P2860
P2888
P304
P356
10.1007/BF01059688
P577
1977-12-01T00:00:00Z